Cocrystal Pharma EBIT per Share
The EBIT per Share of Cocrystal Pharma (COCP) as of Oct 31, 2026 is -0.80 USD. In the previous year, EBIT per Share was -1.76 USD — a change of -54.54% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.80USD
YoY
-54.54%
Last updated:
The Cocrystal Pharma EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | -1.63USD | +20.00% |
| est | -1.36USD | +69.64% |
| -0.80USD | -54.54% | |
| -1.76USD | -3.67% | |
| -1.82USD | -61.75% | |
| -4.77USD | +143.33% | |
| -1.96USD | -2.48% | |
| -2.01USD | -85.58% | |
| -13.94USD | +572.20% | |
| -2.07USD | -48.99% | |
| -4.07USD | -92.38% | |
| -53.35USD | +91.23% | |
| -27.90USD | +818.37% | |
| -3.04USD | -68.92% | |
| -9.77USD | +680.31% | |
| -1.25USD | -39.45% | |
| -2.07USD | +337.64% | |
| -0.47USD | +1,286.32% | |
| -0.03USD | -93.61% | |
| -0.53USD | -9.22% | |
| -0.59USD | — | |
| 0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cocrystal Pharma Stock analysis
Frequently Asked Questions about Cocrystal Pharma stock
EBIT per Share of Cocrystal Pharma is -0.80 USD in 2025.
EBIT per Share of Cocrystal Pharma changed from -1.76 USD to -0.80 USD, representing a -54.54% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Cocrystal Pharma since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Cocrystal Pharma
All Key Metrics — Cocrystal Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth